PP
MREO

Paloma Partners’s Mereo BioPharma MREO Stock Holding History

Paloma Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-296,659
Closed -$804K – 105
2025
Q2 		$804K Buy
+296,659
New +$716K 0.12% 82

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paloma Partners's MREO Position: Q3 2025 in Review

Paloma Partners sold out of Mereo BioPharma (MREO) in Q3 2025, closing a stake of 296,659 shares — an estimated $804K sold.

Paloma Partners first reported a position in MREO in Q2 2025 and held it in 1 quarter. The position peaked at $804K in Q2 2025. 84 funds tracked by Wall St. Rank hold MREO as of Q3 2025.

  • Paloma Partners reported no remaining Mereo BioPharma position as of Q3 2025 after selling out during the quarter.
  • Paloma Partners sold 296,659 Mereo BioPharma shares in Q3 2025, an estimated $804K.
  • Paloma Partners first reported a position in Mereo BioPharma in Q2 2025 and held it in 1 quarter.
  • Paloma Partners's Mereo BioPharma position peaked at $804K in Q2 2025.
  • 84 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2025.

Based on Paloma Partners's 13F filing for Q3 2025, filed 14 Nov 2025.